1. Home
  2. ELUT vs SERA Comparison

ELUT vs SERA Comparison

Compare ELUT & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELUT
  • SERA
  • Stock Information
  • Founded
  • ELUT 2015
  • SERA 2008
  • Country
  • ELUT United States
  • SERA United States
  • Employees
  • ELUT N/A
  • SERA N/A
  • Industry
  • ELUT Medical Specialities
  • SERA Precision Instruments
  • Sector
  • ELUT Health Care
  • SERA Health Care
  • Exchange
  • ELUT Nasdaq
  • SERA Nasdaq
  • Market Cap
  • ELUT 71.5M
  • SERA 70.4M
  • IPO Year
  • ELUT 2020
  • SERA 2021
  • Fundamental
  • Price
  • ELUT $2.09
  • SERA $2.49
  • Analyst Decision
  • ELUT Strong Buy
  • SERA
  • Analyst Count
  • ELUT 2
  • SERA 0
  • Target Price
  • ELUT $8.00
  • SERA N/A
  • AVG Volume (30 Days)
  • ELUT 20.7K
  • SERA 806.3K
  • Earning Date
  • ELUT 08-06-2025
  • SERA 08-06-2025
  • Dividend Yield
  • ELUT N/A
  • SERA N/A
  • EPS Growth
  • ELUT N/A
  • SERA N/A
  • EPS
  • ELUT N/A
  • SERA N/A
  • Revenue
  • ELUT $23,711,000.00
  • SERA $115,000.00
  • Revenue This Year
  • ELUT $20.10
  • SERA $390.13
  • Revenue Next Year
  • ELUT $85.89
  • SERA $440.54
  • P/E Ratio
  • ELUT N/A
  • SERA N/A
  • Revenue Growth
  • ELUT N/A
  • SERA N/A
  • 52 Week Low
  • ELUT $1.61
  • SERA $1.37
  • 52 Week High
  • ELUT $5.12
  • SERA $9.13
  • Technical
  • Relative Strength Index (RSI)
  • ELUT 58.03
  • SERA 53.89
  • Support Level
  • ELUT $1.95
  • SERA $1.82
  • Resistance Level
  • ELUT $2.23
  • SERA $4.09
  • Average True Range (ATR)
  • ELUT 0.17
  • SERA 0.36
  • MACD
  • ELUT 0.04
  • SERA 0.10
  • Stochastic Oscillator
  • ELUT 73.58
  • SERA 35.74

About ELUT Elutia Inc.

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

About SERA Sera Prognostics Inc.

Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.

Share on Social Networks: